(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 December 2007 (21.12.2007)

PCT

(10) International Publication Number
WO 2007/147090 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2007/071275

(22) International Filing Date: 14 June 2007 (14.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/813,903 14 June 2006 (14.06.2006) US
60/871,361 21 December 2006 (21.12.2006) US

(71) Applicant *(for all designated States except US)*: **MACROGENICS, INC.** [US/US]; 1500 East Gude Drive, Rockville, Maryland 20850-5307 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KOENIG, Scott** [US/US]; 10901 Ralston Road, Rockville, Maryland 20852 (US). **WILDER, Ronald** [US/US]; 7508 Tarpley Drive, Rockville, Maryland 20851 (US). **BONVINI, Ezio** [US/US]; 2 Shetland Court, Rockville, Maryland 20851 (US). **JOHNSON, Leslie, S.** [US/US]; 4411 Poplar Hill Road, Darnestown, Maryland 20874 (US). **PILLEMER, Stanley** [US/US]; 14408 Quietwood Terrace, North Potomac, Maryland 20878 (US).

(74) Agent: **ENMON, Richard**; King & Spalding LLP, 1185 Avenue of the Americas, New York, New York 10036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2007/147090 A2

(54) **Title:** METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY

(57) **Abstract:** The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.